In the Literature
Efforts should focus on initiating use of physical therapy for inpatient pediatric ALL patients, research shows.
Most pediatric patients with ALL achieved complete response after treatment with CD19 CAR T-cell therapy.
Inotuzumab ozogamicin resulted in a high overall response rate, and many ALL patients achieved MRD negativity.
Advertisement
Certain CD19 chimeric antigen receptor (CAR) T-cell products were associated with different levels of adverse events and ...
Minimal residual disease (MRD) negativity after autologous hematopoietic cell transplantation (AHCT) was associated with ...
Even after COVID-19 vaccination, non-Hodgkin lymphoma or CLL patients had low antibody binding and live-virus neutralization.
Advertisement
Study finds that a third dose of the COVID-19 vaccine increased antibodies in multiple myeloma patients, regardless of prior ...
Geriatric Assessment Information Survival Prediction of AML Patients ‘Unfit’ for Intensive Treatment
Certain geriatric assessment measures were associated with survival among older adults with acute myeloid leukemia.
A study of seven clinical trials around CAR T-cell therapies showed a substantially low enrollment of participants who were ...
Immune checkpoint inhibitors can lower the risk of developing neurologic adverse events (NAEs) more than other cancer ...
Researchers inactivated thousands of genes in several adult T-cell leukemia/lymphoma cell lines and found CDK6 to be a ...
Study shows that CD19-directed CAR T-cell therapy may be potential treatment for B-ALL patients with CNS leukemia.
First-line ibrutinib has sustained survival benefit for patients with CLL, according to a long-term follow-up study.
For AML patients who had hematopoietic stem cell transplantation, certain IDH mutations may increase their relapse risk.
Researchers shared additional data on the immune response of patients with chronic myeloid leukemia to COVID-19 infection and ...
At least one-quarter of patients experienced arterial occlusive events (AOE), but rates varied depending on the approach.
Researchers surveyed the reasons for low recruitment and early closure of the UK National Cancer Research Institute’s ...
Researchers examined survival rates by age in patients with Hodgkin lymphoma receiving response-adapted therapy on ...
In patients with high-risk essential thrombocythemia and polycythemia vera, both hydroxyurea and pegylated interferon-α.
Post-transplant response-adapted consolidation therapy with Dara-KRd using MRD led to high rates of MRD negativity in ...
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.